4.8 Article

Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers

期刊

ELIFE
卷 6, 期 -, 页码 -

出版社

ELIFE SCIENCES PUBLICATIONS LTD
DOI: 10.7554/eLife.26857

关键词

-

类别

资金

  1. Cancer Prevention and Research Institute of Texas [DP150096]
  2. Congressionally Directed Medical Research Programs [W81XWH-12-1-0288, W81XWH-13-2-0093, W81XWH-16-1-0294]
  3. Welch Foundation [AT-1595]
  4. National Institutes of Health [CA179120-01, P30 CA-54174]
  5. UTHSA, School of Medicine

向作者/读者索取更多资源

The majority of human breast cancer is estrogen receptor alpha (ER) positive. While anti-estrogens/aromatase inhibitors are initially effective, resistance to these drugs commonly develops. Therapy-resistant tumors often retain ER signaling, via interaction with critical oncogenic coregulator proteins. To address these mechanisms of resistance, we have developed a novel ER coregulator binding modulator, ERX-11. ERX-11 interacts directly with ER and blocks the interaction between a subset of coregulators with both native and mutant forms of ER. ERX-11 effectively blocks ER-mediated oncogenic signaling and has potent anti-proliferative activity against therapy-sensitive and therapy-resistant human breast cancer cells. ERX-11 is orally bioavailable, with no overt signs of toxicity and potent activity in both murine xenograft and patient-derived breast tumor explant models. This first-in-class agent, with its novel mechanism of action of disrupting critical protein-protein interactions, overcomes the limitations of current therapies and may be clinically translatable for patients with therapy-sensitive and therapy-resistant breast cancers.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据